Dallas, Texas 07/25/2013 (Financialstrend) – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had announced on 24 July, 2013 that the management made declaration that Managing Director Fred E. Cohen have got elected to the firm’s board and all the directors and leadership group are very happy about it. They have also announced that Cohen brings a wealth of technical knowledge and biz approach to the company and has been invaluable resource to the group as both an advisor and as a shareholder for many years. They look forward to his leadership and insights in the direction of the further achievement of the firm.
Additionally, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had been promoted by JMP Securities and bagged Outperform position in a study note. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had previously declared its earning outcomes on May 7, 2013 and the firm registered for the quarterly period as EPS of $0.09. The income of the firm was registered as $3.60 million.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had lost 0.44% on Wednesday to close at $4.50 per share, after opening the day at a price of $4.46 per share. The stock had through the day moved with prices fluctuating between $4.31 and $5.02 per share. The company presently has 52 week low at $1.08 and 52 week high at $5.02. The institutional holding is at 32% and there are 53.15 million shares outstanding in the market with a market cap of the stock presently at $239.16 million.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biotechnology enterprise that designs, optimizes and develops drugs, which block enzymes occupied in the pathogenesis of diseases. The firm focuses on biology, crystallography, chemistry and computer modeling, therapeutic areas and the product is Peramivir that is a neuraminidase inhibitor for the treatment of patients suffering with influenza.